Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
P/S ratio for Adicet Bio, Inc. (ACET)
P/S ratio as of 2023: 0.00
According to Adicet Bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 14.70.
P/S ratio history for Adicet Bio, Inc. from 2008 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 14.70 |
| 2021 | 55.64 |
| 2020 | 5.74 |
| 2019 | 156.95 |
| 2018 | 219.78 |
| 2017 | 0.54 |
| 2016 | 0.58 |
| 2015 | 0.55 |
| 2014 | 0.54 |
| 2013 | 0.54 |
| 2012 | 0.59 |
| 2011 | 0.62 |
| 2010 | 0.72 |
| 2009 | 0.75 |
| 2008 | 0.67 |